ETOP ADOPT

About this trial

Durvalumab is is an immune checkpoint inhibitor and a type of monoclonal antibody that treats certain cancers by blocking PD-L1, a protein that prevents immune cells from attacking cancer cells. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body. Durvalumab prevents PD-1 from switching off these immune cells. This increases the ability of the immune system to kill tumour cells. Durvalumab is sold under the name Imfinzi.
The purpose of this study is to:
Evaluate the efficacy and safety of adding adjuvant durvalumab (adjuvant treatment in cancer is treatment given after primary treatment such as surgery) after neoadjuvatnt chemo plus durvalumab (neoadjuvant treatment is given before the primary treatment to shrink a tumour) for patients with Stage IIB-IIIB (N2) resectable NSCLC. The study hopes to determine if additional adjuvant immuno therapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on Disease Free Survival (the length of time after cancer treatment that a patient does not have any signs or symptoms of the cancer returning).
Patients who are eligible to participate on this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomization. Patients assigned to treatment group one will the adjuvant durvalumab. Patients assigned to treatment group two will not recieve an adjuvant treatment. Patients will be asked to visit the study doctor for study treatment for up to 48 weeks, as long as their cancer is not getting worse or they do not have serious side effects. About 290 people will be in the study in total.

Patient Profile

Stage IIB-IIIB (N2) resectable NSCLC

Where’s this trial being run?

Beaumont Hospital and St James’s Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	ETOP ADOPT
Number:	23-23
Full Title:	A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Principal Investigator:	Prof Patrick Forde
Type:	Collaborative
Sponsor:	ETOP IBCSG Partners Foundation
Recruitment Started:	Global: Jan 2025 Ireland:

Global Recruitment Target:	290
Ireland Recruitment Target: